✦ LIBER ✦

Immunosuppressive treatment of HBsAg-positive chronic liver disease: Significance of HBeAg

✍ Scribed by Ulrik Tage-Jensen; Jan Aldershvile; Poul Schlichting

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 294 KB
Volume: 5
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840050111

No coin nor oath required. For personal study only.

✦ Synopsis

In a randomized clinical trial in 148 patients of azathioprine vs. prednisone treatment of chronic aggressive hepatitis and/or nonalcoholic cirrhosis, 20 were HBsAg positive on entry. In this subgroup sequential serum samples were investigated for HBs and HBe markers by radioimmunoassay. At the time of evaluation, 13 patients were still alive; their median age was 5 3 years (25 to 72) and median follow-up time was 46 months (23 to 82).

Of 16 patients with cirrhosis, 5 of 7 with persistence of HBeAg died, compared with 2 of 9 with anti-HBe. In three patients with anti-HBe, HBeAg reappeared several times with simultaneous rise in transaminase values.

The overall survival was 65% after 5 years. The prognosis of HBsAg-positive chronic liver disease seemed to depend on the presence of cirrhosis and HBeAg rather than on improvement in biochemical activity during immunosuppressive treatment.

📜 SIMILAR VOLUMES

Immunosuppressive treatment of chronic H

Immunosuppressive treatment of chronic HBsAg-positive hepatitis in childhood

✍ P. Tolentino; C. Jannuzzi; R. Giacchino 📂 Article 📅 1983 🏛 Springer-Verlag 🌐 English ⚖ 887 KB

Effect of Immunosuppressive Therapy on H

Effect of Immunosuppressive Therapy on HBsAg-Positive Chronic Active Hepatitis in Relation to Presence or Absence of HBeAg and Anti-HBe

✍ Evangelista Sagnelli; Felice Piccinino; Giuseppe Manzillo; Francesca M. Felaco; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 556 KB

Two hundred and four patients with biopsy-proven HBsAg-positive chronic active hepatitis were treated for at least 2 years with azathioprine, prednisolone or a combination of both, or were untreated. Prevalences of HBeAg, anti-HBe, and anti-HBc were 26, 58, and loo%, respectively. Criteria for impro

New perspectives in the treatment of HBe

New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B

✍ Thomas Berg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term

Treatment of HBsAg-Positive chronic acti

Treatment of HBsAg-Positive chronic active hepatitis with corticosteroids and/or azathioprine

✍ Giuseppe Manzillo; Felice Piccinino; Evancelista Sagnelli; Crescenzo Maria Izzo; 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 429 KB

Randomized Controlled Trial of Quinacrin

Randomized Controlled Trial of Quinacrine for the Treatment of HBsAg-Positive Chronic Hepatitis

✍ Henry C. Bodenheimer Jr.; Fenton Schaffner; Salvatore Vernace; Shalom Z. Hirschm 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 1 views

Several drugs which react with DNA decrease hepatitis B viral (HBV) DNA polymerase activity in vitro. Because such an alteration of viral replication, if produced in patients with hepatitis B surface antigen (HBsAg)-positive chronic hepatitis, may lead to elimination of viral infection, we conducted

Significance of serum and hepatic marker

Significance of serum and hepatic markers of hepatitis B viral infection in HBsAg-positive and HBsAg-negative chronic active hepatitis

✍ John Freiman; Robert Eckstein; Geoffrey McCaughan; Carolyn Parsons; J. Stuart Da 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 396 KB 👁 1 views

CAH based on established criteria (7) and evidence of liver disease for greater than 6 months, were included in this study. Age, sex, drug history, alcohol intake and predisposing factors to HBV infection were recorded.